MANCHESTER, United Kingdom, June 18, 2025 (GLOBE NEWSWIRE) -- F2G Ltd, a clinical-stage biopharmaceutical company developing olorofim, a novel therapy to treat life-threatening rare fungal infections ...
UK biotech F2G has raised $100 million as it prepares to refile its olorofim candidate for invasive fungal infections, which was turned down last year by the FDA. The Manchester-based company said the ...
- Brings substantial pharmaceutical expertise to lead the development and commercialization of olorofim in the USA - Ian Nicholson stepping down to pursue non-executive roles MANCHESTER, England and ...
Data reinforce olorofim's potential as a first-in-class treatment for patients with invasive fungal diseases and limited or no antifungal treatment options MANCHESTER, United Kingdom, June 18, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback